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Abstract
CYP1A1, a cytochrome P450 enzyme, metabolizes polycyclic
aromatic hydrocarbons to genotoxic metabolite(s) that bind to
DNA and initiate carcinogenesis. RT-PCR amplification of the
complete open reading frame of CYP1A1 generated an
amplicon of 1593 bp having deletion of 87 bp of exon-6 that
translated into functional P450 enzyme. Unlike wild type
CYP1A1, exon 6 del CYP1A1 did not metabolize polycyclic
aromatic hydrocarbons such as, benzo(a)pyrene to genotoxic,
ultimate carcinogens that form DNA adducts. Exon 6 del
CYP1A1 metabolized ethoxyresorufin (the classical substrate
for CYP1A1) less efficiently compared with wild type CYP1A1
while pentoxy and benzyloxyresorufin (classical substrates for
CYP2B) were dealkylated more efficiently. In silico docking
showed alteration of the substrate access channel in exon 6
del CYP1A1 such that benzo(a)pyrene does not bind in any
orientation that would permit the formation of carcinogenic
metabolites. Genotyping revealed that the splice variant was
not generated due to differences in genomic DNA sequence
and the variant was present only in brain but not in liver,
kidney, lung, or heart from the same individual. We provide
evidence that unique P450 enzymes, generated by alternate
splicing in a histiospecific manner can modify genotoxic
potential of carcinogens such as benzo(a)pyrene by altering
their biotransformation pathway.
Keywords: benzo(a)pyrene, carcinogenesis, target organ
toxicity, xenobiotic metabolism.
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Cytochrome P450 (E.C. 1.14.14.1; P450), a superfamily of
heme proteins, is involved in the metabolism of a vast array
of carcinogens, drugs, and endogenous compounds. Liver is
the major organ involved in P450-mediated xenobiotic
metabolism (Conney 2003). However, the importance of
extrahepatic metabolism has been increasingly recognized
especially with respect to their potential role in target organ
toxicity. The preferential localization of xenobiotic metabo-
lizing enzymes within specific cell types in these organs
renders such cells a remarkable capacity to metabolize
foreign compounds including carcinogens (McLemore et al.
1990; Hedlund et al. 2001). Studies from our laboratory and
others have demonstrated the presence of a competent
microsomal P450 system in rodent (Anandatheerthavarada
et al. 1990) and human brain (Ravindranath et al. 1989) and
its ability to metabolize a variety of xenobiotics (Ravindra-
nath and Boyd 1995; Ravindranath et al. 1995).
Cytochrome P4501A1 (CYP1A1), a member of the P450
super family, is a major extrahepatic enzyme, and is induced
upon administration of 3-methylcholanthrene, b-naphthof-
lavone or 2,3,7,8-tetrachlorodibenzo-p-dioxin (Jones et al.
1986). CYP1A1 contributes notably to the toxicity of many
carcinogens, especially polycyclic aromatic hydrocarbons
(PAHs), as it is the principal enzyme that bio-activates inert
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hydrocarbons into DNA-binding reactive metabolites (Park
et al. 1996). The presence of CYP1A1 in brain could
potentially play a role in the initiation of carcinogenesis
in situ, as PAHs are lipophilic and can cross the blood brain
barrier. Several epidemiological studies (Inskip et al. 1995)
carried out on workers in petroleum industry (Burch et al.
1987; Lee et al. 1997) and on smokers (a major source of
PAH exposure) have shown association with brain tumor
incidence. GSTM3 allele is associated with brain tumor
incidence (De Roos et al. 2006). Further, within the
subgroup having GSTM3 allele, a stronger association was
found between smoking and brain tumor incidence. Further
induction of CYP1A1 enzyme by PAHs increases the
generation of reactive oxygen species, which may cause
oxidative damage in brain (Strolin-Benedetti et al. 1999).
Significant differences are seen in the metabolism of
psychoactive drugs mediated by brain and liver P450
enzymes. For example, drugs, such as, alprazolam are
metabolized differently in liver and brain wherein relatively
larger amount of the active metabolite is generated in brain
compared with liver (Pai et al. 2002). These observations
have indicated the possible existence of unique P450
enzymes in the brain that are different from the well-
characterized hepatic P450s. RT-PCR amplification of exon 3
to 7 of CYP1A1 RNA demonstrated the presence of a
transcript having deletion of exon 6 in human brain but not in
liver (Chinta et al. 2005). Sequence analysis indicated that
the deletion of exon 6 in CYP1A1 does not lead to premature
termination or frame shift. Therefore, we attempted to clone
full-length exon 6 del CYP1A1 and characterize the function
of the unique splice variant that is generated by alternate
splicing in human brain, but not in liver or kidney.
Materials and methods
Materials
3-Hydroxy benzo[a]pyrene (3-OH-BP) was obtained from the
National Cancer Institute Chemical Carcinogen Reference Standard
Repositories at Midwest Research Institute (Kansas City, MO, USA).
Monoclonal antibody against rat P4501A1 was a gift from Dr Paul E.
Thomas, Rutgers University, USA. Polyclonal antibody against
b-actin was purchased (Clontech, Mountain View, CA, USA).
Human Tissue
Human brain and other tissues were obtained at autopsy from male
and female traffic accident victims with no known neurological or
psychiatric disorders through the Human Brain Tissue Repository,
Department of Neuropathology, NIMHANS. The material was
collected at postmortem in accordance to the ethical guidelines of
the Government of India. The average age of the individuals was
38.2 years ± 18.9 (7–72 years) and postmortem delay between
death and autopsy was 5.50 ± 2.45 h. Total RNA was isolated
from human autopsy tissues and used for RT-PCR (Chomczynski
1993).
RT-PCR amplification of exons 3–7 of CYP1A1
RT-PCR was carried out using 25 autopsy human brain samples and
human brain cortex, liver, lung, kidney, and heart from the same
individual using forward and reverse primers, 5¢ -TGGATGAGA
ACGCCAATGTC-3¢ and 3¢-TGGGTTGACCCATAGCTTCT-5¢,
respectively.
RT-PCR amplification of complete ORF of CYP1A1
RT-PCR was performed using forward and reverse primers; 5¢-
GAACCTTCCCTGATCCTTGTG-3¢ and 5¢-GCCCAGATAGCAA-
AACTGCA-3¢ (27–1798), respectively. The RT-PCR product was
used as template for nested PCR using the forward and reverse
primers; 5¢-TTGTGATCCCAGGCTCCAAG-3¢ and 5¢-GGTCTG-
GCTGCCCAACCA-3¢ (43–1720), respectively. RT-PCR amplifica-
tion of the complete ORF of CYP1A1 resulted in the generation
of exon 6 del CYP1A1 (GenBank Accession No. AY871801) in
four samples, while wild type CYP1A1 (GenBank Accession No.
NM_000499) was amplified in one sample. The amplicon was
ligated into pcDNA 3.1 vector for expression studies.
Amplification of genomic DNA by PCR
Genomic DNA was extracted from human brain cortex and PCR
was performed using forward and reverse primers, 5¢-GCTGCC-
TGCCTAACTTCTTCT – 3¢ and 5¢-AGCAGGATAGCCAGGAA-
GAGA-3¢, respectively to amplify the genomic DNA from exons
3–7.
PCR amplification of exon 6 of CYP1A1
Polymerase chain reaction amplification was performed using
primers from the flanking regions namely, exons 5 and 7 (forward
and reverse primers, 5¢-CCCTTCACCATCCCCCACA-3¢, and 5¢-
ATGGGTTGACCCATAGCTTCT-3¢). pCR 2.1 vector (TA Cloning
Vector, Invitrogen Corporation, USA) containing the complete ORF
of wild type CYP1A1 was used as template. The expected size of the
PCR product was 127 bp, which consisted of 87 bp of exon 6 and
the flanking regions of exons 5 and 7.
Immunoblotting with membrane preparations from transfected
cells
Membrane preparations containing both microsomal and mitoch-
ondrial protein (50 lg) isolated from Neuro2a cells (Pai et al. 2004)
expressing wild type and exon 6 del CYP1A1 were analyzed
by SDS-PAGE and transferred to nitrocellulose membrane. The
blots were incubated sequentially with antiserum to rat P4501a1
(Anandatheerthavarada et al. 1990) and anti-rabbit IgG conjugated
to alkaline phosphatase. Color was developed using chromogenic
substrates for the alkaline phosphatase.
Assay of total P450 content and dealkylation of alkoxy
resorufins
Total cytochrome P450 content in the membrane preparation from
Neuro2a cells expressing CYP1A1 variants was measured from
carbon monoxide reduced minus oxidized difference spectrum.
O-Dealkylation of alkoxy resorufin was performed in microtitre
plates as described (Kennedy and Jones 1994). Incubations
performed in the absence of NADPH were incorporated as controls.
Similar experiments were also performed following pre-incubation
of the membranes with antiserum to P4501a1 for 30 min at 25C
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prior to the addition of substrate and NADPH. Formation of
resorufin was measured fluorimetrically using 530 nm for excitation
and 590 nm for emission.
Identification of DNA adducts by 32P-post-labeling
COS-1 cells were transfected with cDNA to wild type and exon 6
del CYP1A1 in both orientation, and were treated with benzo[a]py-
rene (BP; 1 lmol/L), 3-methylcholanthrene (MC; 1 lmol/L), or
vehicle for 16 h. DNA was isolated and nuclease-P1-enhanced
version of the 32P-post-labeling assay for DNA adducts was
performed (Reddy and Randerath 1986). The labeled products were
separated by two-dimensional polyethyleneimine-cellulose thin-
layer chromatography (Moorthy and Randerath 1996) and exposed
to autoradiography.
Aryl hydrocarbon hydroxylase (AHH) activity
AHH activity was assayed in cell lysates expressing both wild type
and exon 6 del CYP1A1 (Nebert and Gelboin 1968). The expression
level of CYP1A1 was ascertained by western blotting using
P4501A1-specific antibodies and normalized using b-actin.
Localization of exon 6 del CYP1A1 in cells and tissue by in situ
hybridization
The 127 bp PCR product representing exon 6 was ligated into
pCRII vector and digoxigenin labeled sense and antisense ribo-
probes were generated. Digoxigenin labeled riboprobes were also
generated from the complete ORF of exon 6 del CYP1A1 (GenBank
No. AY871801). In situ hybridization was performed using paraffin
embedded sections of brain, liver, and kidney from the same
individual (Pai et al. 2004). Neuro2a cells were grown in chamber
slides, fixed with buffered paraformaldehyde (4%, w/v) and
processed for in situ hybridization.
In silico docking studies
AUTODOCK 3.0 was used to dock BP with wild type and exon 6
del CYP1A1 (Morris et al. 1998). All water molecules were
(a) (b)
(f)
(h)
(i)
(g)
(c) (d) (e)
Fig. 1 Amplification and expression of CYP1A1 variants from human
brain. (a & b): Exons 3 to 7 of CYP1A1 cDNA was amplified by RT-
PCR from 25 samples of human brain cortex obtained at autopsy. An
amplicon of 305 bp indicating deletion of exon 6 was observed in all
samples except one (Sample I), which showed the presence of exon-6
(392 bp; lane 15 in b). (c) Mitochondria and microsomes (50 lg) from
cells transfected with sense (lanes 1 & 2) and antisense (lane 3) wild
type CYP1A1 cDNA and sense (lanes 4 & 5) and antisense (lane 6)
exon 6 del CYP1A1 were immunostained with antiserum to P4501a1.
Dithionite reduced carbon monoxide binding spectrum of membrane
preparations from Neuro2a cells expressing exon 6 del (d) and wild
type P4501A1 (e) protein. The P450 specific content was 0.984 and
1.15 nmoles of P450/mg protein for exon 6 del and wild type P4501A1.
The complete ORF of exon 6 del CYP1A1 was amplified from 4 human
brain samples (f) and wild type CYP1A1 was amplified from one
sample (g). ‘M’ indicates molecular weight markers. ‘N’ indicates
negative control. (h) Exons 3–7 of CYP1A1 cDNA was PCR amplified
in two samples of human brain cortex (1 and 2) and an amplicon of
305 bp was detected indicating the deletion of 87 bp of exon 6.
Sequencing revealed the G fi A substitution in the 3¢ end of exon 5. (i)
Genomic DNA sequence of the region exon 5–7 was similar in the
samples 1 and 2. The genomic DNA sequence was also identical in
the individual who expressed wild type CYP1A1.
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removed except two that bind to backbone atoms of residues in the I
helix since AUTODOCK uses implicit solvation parameters. The
four backbone residues binding waters are G293, A294, E297, and
T298 in the crystal structure of the CYP2C5 template, and these
residues are understood to be directly involved in proton transport
during catalysis (Wester et al. 2003). The corresponding residues in
the wild type and exon 6 del CYP1A1 homology models are
conserved. All non-polar hydrogens were merged to the connected
carbon atom and Kollman united-atom charges were added. The
heme charges were dealt with separately being generously provided
by Dr Mark Paulsen (Northern Michigan University) in which atom
assignments were made with quantum mechanical derivations
providing an electrostatic potential fit. ChemDraw Ultra and Chem
3D Pro programs within ChemOffice were used to prepare the BP
coordinates and minimize the structure. BP is a rigid molecule,
therefore; there were no rotatable bonds to be considered. Grid
maps were generated with AUTOGRID. Affinity grid dimensions
were 86 A˚ · 84 A˚ · 86 A˚ with a spacing of 0.425. The three-
dimensional grid was mainly located on the distal side of the heme
where one edge was slightly protruding below the plane of the
heme. This allowed the entire distal portion of both proteins to be
sampled through conformational space for potential binding sites.
The Lamarckian genetic algorithm was used to test docking
conformations and the beginning BP state was located outside of
the protein near F–G loop. A total of fifty dockings were performed
for both proteins with a population size of 50 individuals, a
maximum of 250 000 energy evaluations, 27 000 maximum
number of generations, a mutation rate of 0.02, a crossover rate
of 0.8 and only one individual was allowed to survive to the next
generation.
Results
Cloning and expression of CYP1A1 from human brain
The region spanning exons 3 to 7 of CYP1A1 cDNA was
amplified by RT-PCR using total RNA from 25 samples of
human brain cortex obtained at autopsy. An amplicon
of 305 bp was observed in all samples indicating absence
of exon 6, except in one sample, wherein a 392 bp amplicon
was observed, indicating that the individual (lane 15 of
Figs 1a and b) expressed the wild type CYP1A1. We were
unable to detect 2 bands in any samples, which would have
indicated the presence of both wild type and exon 6 del
CYP1A1. We then amplified the complete ORF of CYP1A1
from five human brain samples including the brain sample
that showed the presence of the wild type CYP1A1. PCR
product of 1593 bp was seen in four samples (Fig. 1f) while
1680 bp product was seen in the brain sample mentioned
above (Fig. 1g). Sequencing revealed that 1593 bp amplicon
was devoid of 87 bp of exon-6 (GenBank No. AY871801)
and 1680 bp amplicon was similar to wild type CYP1A1
(GenBank No. NM_000499). When Neuro2a cells were
transfected with cDNAs encoding exon 6 del CYP1A1, the
expressed protein was a functional P450 similar to that seen
in cells transfected with wild type CYP1A1 as ascertained
from the reduced carbon monoxide difference spectra
(Figs 1d and e). The expressed protein could also be detected
by immunoblotting using antiserum to P4501a1 (Fig. 1c).
(a) (d)
(e)
(b)
(c)
Fig. 2 Dealkylation of alkoxy resorufins by
CYP1A1 variants from human brain. Mem-
brane preparations containing both mito-
chondria and microsomes from Neuro 2A
cells expressing wild type and exon 6 del
P4501A1 were incubated with ethoxy (a),
pentoxy (b) and benzyloxy (c) resorufin and
the formation of resorufin by O-dealkylation
was measured. Preincubation with anti-
serum to P4501a1 inhibits dealkylation of
ethoxy (d) and benzyloxy (e) resorufin.
Values are depicted as NADPH dependent
rates and are mean ± SD (n = 3 individual
experiments). Cells transfected with cDNA
in reverse orientation were incorporated as
controls.
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Cells transfected with cDNAs in the reverse orientation did
not have any detectable P450 as examined by immunoblot
and P450 assay (data not shown).
RT-PCR amplification of exons 3–7 of CYP1A1 from two
human brain samples (1 and 2 of Fig. 1h) yielded a 305 bp
product indicating the presence of exon 6 delCYP1A1. In sample
1, the 3¢ end of exon 5 showed a G fi A substitution as
comparedwith sample 2. Inorder to determine if this substitution
was the result of changes in genomic DNA sequence, we
amplified the region spanning exons 3–7 using genomic DNA
from human brain. The genomic DNA sequences of the sample
from the individual who expressed wild type CYP1A1 (Fig. 1i;
Fig. S1) andnot the exon6delCYP1A1were identical to samples
1 and 2 which expressed only exon 6 del CYP1A1.
Dealkylation of alkoxy resorufin by exon 6 del P4501A1
Membrane preparations containing both mitochondria and
microsomes were prepared from Neuro2a cells transfected
with cDNAs to CYP1A1 variants. Exon 6 del P4501A1
deethylated ethoxyresorufin, the classical substrate of
P4501A1 much less efficiently compared with wild type
P4501A1 (Fig. 2a), whereas pentoxy and benzyloxy resoru-
fin, classical substrates of P4502B were dealkylated more
efficiently by exon 6 del P4501A1 compared with wild type
P4501A1 (Fig. 2b and c). Dealkylation of ethoxy and
benzyloxy resorufin could be inhibited by antiserum to
P4501a1 indicating that this biotransformation was indeed
mediated by P4501A1 (Fig. 2d and e).
(a) (b)
(i) (v) (ix)
(ii) (vi) (x)
(iii) (vii) (xi)
(iv) (viii) (xii)
Fig. 3 Bioactivation of PAH to DNA binding adducts by CYP1A1
variants. (a) Biotransformation pathway of BP bioactivation to DNA
adduct formation. The major metabolic activation pathway of BP en-
tails the CYP1A1-dependent metabolic activation at the 7, 8 bond to
yield an epoxide, which then undergoes epoxide hydrolase-mediated
hydration to BP-7, 8-diol. BP-7, 8-diol is in turn transformed to BPDE
by CYP1A1-mediated epoxidation at the 9,10 position. The major
BPDE-DNA adduct results from nucleophilic attack of the exocyclic N2
position of guanine on the C-10 position of (+)-anti-BPDE. (b) COS-1
cells were transfected with cDNA to wild type or exon 6 del CYP1A1
for 24 h, followed by treatment with DMSO (i–iv, vehicle), BP (1 lmol/
L) (v–viii), or MC (1 lmol/L) (ix–xii), as described under Materials and
Methods. DNA adducts were analyzed by 32P-post-labeling. (+) and
()) denote plasmids containing cDNAs that were cloned in the sense
and antisense orientation, respectively.
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Formation of DNA adducts by metabolites of polycyclic
aromatic hydrocarbons
The mechanism by which BP interacts with DNA and initiates
carcinogenic processes involves the formation of a biologic-
ally active carcinogen, BP-7,8-diol-9,10-epoxide (BPDE;
Fig. 3a). BP or MC, but not vehicle, induced the formation
of multiple adducts in cells transfected with wild typeCYP1A1
cDNA (Fig. 3b). BP and MC gave rise to 5 (nos. 1–5) and 8
(nos. 1–8) adduct spots, respectively. Similar DNA adducts
were not detectable in BP or MC-exposed cells that were
transfected with the exon 6 del CYP1A1. Metabolism of BP to
3-OH-BP by exon 6 del P4501A1.
Metabolism of BP to 3-OH-BP by exon 6 del P4501A1
Cells transfected with wild type CYP1A1 efficiently hydr-
oxylated BP to 3-hydroxy benzo[a]pyrene. However, cells
expressing exon 6 del CYP1A1 failed to hydroxylate BP and
no activity was detectable (Fig. 4a). In fact, the response was
similar to the cells that were transfected with CYP1A1 cDNA
(reverse orientation). In order to ensure that the transfection
efficiency was similar amongst the experiment groups, we
performed immunoblot experiments using antibody to rat
P4501a1, which cross-reacts with human P4501A1. The
transfection efficiency did not vary significantly between the
different groups (Fig. 4b).
Localization of exon 6 del and wild type CYP1A1 mRNA
by fluorescence in-situ hybridization
Neuro2a cells transiently transfected with wild type or exon 6
del CYP1A1 showed intense staining when hybridized with
full-length cDNA to exon 6 del CYP1A1. However, cells
transfected with exon 6 del CYP1A1 showed no staining
(Fig. 5b) when hybridized with the probe representing exon
6 alone. Neuro2a cells transfected with wild type or exon 6
del CYP1A1 in reverse orientation did not exhibit any
fluorescence. The corresponding nuclear staining of the cells
with DAPI is shown in Fig. 5b.
CYP1A1 variants in human brain, lung, liver, and kidney
In situ hybridization was performed using 127 bp amplicon
representing exon 6 of CYP1A1 using human brain, liver and
kidney sections from the same individual. Expression of
exon 6 of CYP1A1 was detected in liver and kidney but not
in the brain from the same individual (Fig. 6a) indicating that
the CYP1A1 transcript in brain did not contain exon 6.
However, when in situ hybridization was carried out using
full-length exon 6 del CYP1A1, the expression of the same
could be discerned in the cortical neurons of the human
brain. The region spanning exons 3–7 of CYP1A1 cDNAwas
amplified by PCR using cDNA synthesized from total RNA
of human brain, liver, kidney, lung and heart tissues from the
same individual obtained at autopsy. An amplicon of 305 bp
(Fig. 6b; lane 1) was observed in brain but not in the other
tissues wherein an amplicon of 392 bp was observed
indicating the expression of wild type CYP1A1.
Docking studies
Our docking experiments predict that BP may have two
major binding orientations in the CYP1A1 active site. The
first cluster presents the 7, 8, 9, 10 aromatic ring near the
heme iron with a docking energy of )10.00 kcal/mol
(Fig. 7a) and the second cluster presents position 3 close to
the heme iron with a docking energy of )9.86 kcal/mol
(Fig. 7b). There was a total of six clusters found using a 0.5A
root mean square cut off acceptance value. Cluster 1
represents 36/50 (72%) and cluster 2 represents 7/50 (14%)
of the docking conformations. The remaining clusters were
not included since they had fewer than 3 representative
dockings. BP also has two main docking clusters out of 11
found for exon 6 del CYP1A1 and both are situated in a
manner where position 3 is in close proximity to the iron
(Figs 7c and d). Cluster 1 represents 16/50 (32%) dockings
with –9.81 kcal/mol docking energy and cluster 2 represents
10/50 (20%) with –9.74 kcal/mol docking energy.
(a)
(b)
Fig. 4 Aryl hydrocarbon hydroxylase activity (a) and immunoblot (b)
analyses of protein pellets from cells transfected with cDNA to exon 6
del and wild type CYP1A1. (a) AHH activity is expressed as pmol of 3-
hydroxybenzo[a]pyrene formed per min per mg protein in cells trans-
fected with wild type and exon 6 del CYP1A1 cDNA in forward (+) and
reverse ()) orientation. Data is represented as mean ± sd of 3 inde-
pendent transfection experiments performed in triplicate. (b) Immu-
noblot of transfected cells using monoclonal antibody to rat P4501a1.
Lanes 1, 2, and 3 represent protein samples (100 lg) from three
independent transfection experiments for the wild type CYP1A1 or
exon 6 del CYP1A1 constructs. Lanes 4 and 5 represent proteins from
cells transfected with the constructs, cloned in reverse orientation. The
blots were normalized with b-actin antibody. The ratios of pixel den-
sities of wild type CYP1A1 and the variant protein normalized to those
of b-actin were 0.42 ± 0.04 and 0.49 ± 0.07, respectively.
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Discussion
The presence of unique, tissue-specific P450 enzymes
generated through alternate splicing (Pai et al. 2004; Chinta
et al. 2005) provides a mechanism by which active metab-
olites can be potentially formed at site of action of
xenobiotics within the target organ, the brain. The constitu-
tive expression of CYP1A1 in rat and human brain has been
demonstrated by RT-PCR amplification of selected regions of
CYP1A1 gene (Schilter and Omiecinski 1993; McFayden
et al. 1998). We now present the expression and functional
characterization of the exon 6 del CYP1A1 variant from
human brain. Genomic DNA sequence did not reveal any
significant difference between the two samples expressing
wild type and exon 6 del CYP1A1 indicating that the
alternate splicing events governing the deletion of exon 6
were not related to genetic polymorphism of genomic DNA.
Another point of interest was the single base substitution
(G fi A) seen in the cDNA sequence representing 3¢ end of
exon 5 in two samples both of whom expressed exon 6 del
CYP1A1, notwithstanding their identical genomic DNA
sequence (Figs 1h and i). Further, the exon 6 del CYP1A1
was detected only in brain but not in lung, liver, or kidney
from the same individual, implying brain-specific splicing
events. Nervous system has a propensity for generating
alternate spliced forms and splicing defects may not be
related to differences in genomic sequence but may be
regulated by mechanisms involving spliceosomal complex
and RNA binding proteins, which are poorly understood
(Grabowski and Black 2001).
CYP1A1 enzyme is primarily involved in metabolic
activation of PAHs (Fig. 3a) and other environmental
chemicals to reactive intermediates that can form DNA
adducts, critical molecular events in the initiation of carcin-
ogenesis (Thakker et al. 1976). Exon 6 del CYP1A1 in
human brain is unable to bioactivate PAHs to metabolites
(a)
(b)
(i)
(v)
(ix)(ii)
(vi)
(x)(iii)
(vii)
(xi)
(iv)
(viii) (xii)
(xiii)
(xiv)
(xv)
(xvi)
Fig. 5 Detection of exon 6 del CYP1A1 by
in situ hybridization. (a) cDNA to complete
open reading frame of wild type CYP1A1
was used as template to amplify a 127 bp
product representing exon 6 (87 bp) along
with flanking regions of exons 5 and 7. ‘M’
indicates molecular weight markers. ‘N’
indicates negative control. (b) Neuro 2A
cells were transfected with wild type (i, ii, xi,
x) and exon 6 del (v, vi, xiii, xiv) CYP1A1
and hybridized with 127 bp amplicon rep-
resenting exon-6 of CYP1A1 (i–viii) or full-
length exon 6 del CYP1A1 (ix–xvii). The
region representing exon 6 was detected
only in cells transfected with wild type
CYP1A1 (i), while hybridization with the full-
length exon 6 del CYP1A1 resulted in
fluorescent staining in both sets of trans-
fected cells. The corresponding DAPI
stained images are also depicted. Bar =
50 lm.
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that could covalently bind to DNA while multiple DNA
adducts were formed in PAH-exposed cells that were
transfected with wild type CYP1A1. Further, RT-PCR
experiments clearly demonstrate that human brain samples
which express exon 6 del CYP1A1 do not express the wild
type CYP1A1 indicating that in these brain tissues, the PAH
would not be bioactivated to DNA binding metabolites.
Following exposure to BP, the major DNA adducts formed
in cells transfected with wild type CYP1A1 cDNAwere most
likely derived from 7(R),8(S)-dihydroxy-9 (S), 10 (R) epoxy-
7,8,9,10-tetrahydrobenzo[a]pyrene (BPDEI; Fig. 3a). The
BP adducts seen in Fig. 3b, based on their chromatographic
behavior, appear to have been derived from binding of (+)
anti-BPDE1 to N2 of deoxyguanosine. The major adduct (no.
4) results from nucleophilic attack of the exocyclic N2
position of guanine on the C-10 position of (+)-anti-BPDE
(Jerina et al. 1991). Because of the possibility of both cis and
trans addition of the nucleophile, anti-BPDE forms three
(a)
(b)
(i)
(ii)
(iii)
(iv)
(v)
(vi)
Fig. 6 Detection of mRNA of CYP1A1
variants in human tissues. (a) Exon 6 of
CYP1A1 transcript was localized in liver
and kidney but not in cortical neurons of
human brain from the same individual (ii, iii
and i, respectively). The transcript repre-
senting the full-length CYP1A1 gene was
detectable in brain, liver and kidney (iv, v
and vi, respectively). Insets depict corres-
ponding control sections hybridized with
sense riboprobes. Bar = 50 lm except in
the liver, where bar = 25 lm. (b) Exon 3–7
of the CYP1A1 gene was amplified by RT-
PCR from of human brain, liver, kidney,
lung and heart (lanes 1–5, respectively)
from the same individual obtained at aut-
opsy. An amplicon of 305 bp was observed
in brain while an amplicon of 392 bp rep-
resenting inclusion of exon 6 was seen in
other tissues. ‘M’ indicates molecular
weight markers. ‘N’ indicates negative
control.
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other covalent adducts (nos. 1–3; Hall and Grover 1990). The
identity of adduct number 5 is not known, but is probably
formed by the reaction of anti-BPDE with deoxyadenosine.
MC-DNA adducts also appear to have derived from
dihydrodiol epoxides.
In silico binding of BP in the active site of CYP1A1
suggests two main binding orientations, one in which the
substrate sits in a manner to allow the formation of the
reactive ultimate diol epoxide carcinogen (cluster 1) and the
other presents position 3 nearest to the heme iron (cluster 2),
which would likely produce the 3-OH BP non-carcinogenic
metabolite. BP does not appear to bind exon 6 del CYP1A1
in any orientation permissible of generating the carcinogenic
diol epoxide. All sites considered reactive in the docking
were within 5.5 A˚ from the heme iron, which offers a
reasonable distance for oxidation (de Graaf et al. 2005).
The difference in binding modes between these two
enzymes may lie partly in the repositioning of F345 in exon 6
del CYP1A1, which is part of substrate recognition site 5
(SRS5). This residue is adjacent to that portion of the protein
deleted by the alternative splicing of parent CYP1A1 and the
homology model suggests that it may compensate by sliding
closer to the heme in the distal pocket. Therefore, it may
sterically hinder BP from situating where the 7, 8, 9, 10 ring
positions may be oxidized as seen with CYP1A1. This is
confirmed by the in vitro 32P post-labeling data wherein wild
type CYP1A1 made more hydroxylated products than exon 6
del CYP1A1 suggesting that wild type CYP1A1 is more
catalytically efficient at total metabolism of BP than the exon
6 del CYP1A1.
The presence of the CYP1A1 variant in the human brain
and its inability to bioactivate PAHs would render neuro-
protection in individuals exposed to carcinogenic PAHs. This
would be of importance in view of the observed association
between brain tumor incidence and exposure to PAHs (Inskip
et al. 1995). The presence of the splice variant not only has
(a) (b)
(c) (d)
Fig. 7 Docking of benzo(a)pyrene into the active site of CYP1A1
variants. BP is shown in blue and heme shown in red. Aromatic resi-
dues within 10 A˚ of BP capable of p-ring stacking are shown in green.
(a) 72% of the dockings fit within cluster 1, which positions the 7, 8, 9
10 ring closest to Fe-heme. (b) Cluster 2 accounts for 14% of the
dockings, where position 3 is situated near Fe-heme. BP is shown in
blue and heme shown in red. Aromatic residues within 10 A˚ of BP
capable of p-ring stacking are shown in yellow. (c) Cluster 1 comprises
32% of the dockings and position 3 lies close to Fe-heme (d) Cluster 2
makes up 20% and also present position 3 close to Fe-heme.
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implications for metabolism of carcinogens, but also the
metabolism of anti-neoplastic agents (Rooseboom et al.
2004). We now present evidence for the existence of novel
site-specific biotransformation pathways that can potentially
mediate metabolism of xenobiotics at the site of action by
mechanisms that are very different from known pathways in
liver. Identification of novel histio-specific P450 enzymes
generated by alternate splicing of known genes or as yet
unidentified genes may help understand metabolism at site of
action and potentially predict the vulnerability of specific cell
types within tissues to neoplastic transformation mediated
through bioactivation of carcinogens.
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